S3891 More Than Just a Gut Feeling: Unmasking Systemic Mastocytosis Behind Chronic GI Symptoms

Introduction: Systemic mastocytosis is a rare clonal disorder characterized by abnormal proliferation and accumulation of mast cells in multiple organs. Unlike cutaneous mastocytosis, which is confined to the skin, systemic involvement leads to a broad spectrum of symptoms. Gastrointestinal manifestations are common but often non-specific, mimicking other GI disorders and contributing to delayed or missed diagnoses. Early recognition is essential, as symptoms can significantly impact quality of life. We present a case of a 66-year-old woman with debilitating GI symptoms found to be a result of systemic mastocytosis. Case Description/Methods: A 66-year-old woman with a history of hypertension, gastroesophageal reflux disease, Barrett’s esophagus, and osteoporosis presented with decades-long gastrointestinal symptoms, including abdominal pain, bloating, nausea, vomiting, and diarrhea. Symptoms were intermittently triggered by foods such as alcohol and certain breads and seasonings but sometimes occurred spontaneously with nighttime awakenings. An elimination diet failed to identify consistent triggers and workups for common GI disorders, including celiac disease, were unremarkable. Endoscopic evaluation revealed duodenitis and colitis with histologic features raising suspicion for systemic mastocytosis with CD117+ for mast cells. A bone marrow biopsy later reinforced the diagnosis, demonstrating an activating KIT mutation. Tryptase levels were persistently elevated (>20 ng/mL). These findings fulfilled both the major and minor diagnostic criteria for systemic mastocytosis, specifically the indolent variant. After trials with multiple medications, the patient’s symptoms have been controlled with fexofenadine, montelukast, and famotidine. Other medications included cromolyn, which was discontinued due to poor adherence, and a trial drug, Avapritinib, which was stopped due to lower extremity edema and weight gain. Discussion: This case illustrates the diagnostic and therapeutic challenges of GI involvement in systemic mastocytosis. Early diagnosis enables targeted management with a multidisciplinary team and can significantly improve outcomes and quality of life. A low-histamine diet, escalated antihistamine therapy, and consideration of advanced therapies may also provide symptomatic relief and improve quality of life.

Authors

Publication Details

Journal
The American Journal of Gastroenterology
Published
2025-10-01
DOI
https://doi.org/10.14309/01.ajg.0001143024.35878.10
Primary Topic
Mast cells and histamine
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

S3891 More Than Just a Gut Feeling: Unmasking Systemic Mastocytosis Behind Chronic GI Symptoms

Ashley H. Davis-Yadley, Yuri Sánchez González, G Ramírez, Antoine Khoudari
The American Journal of Gastroenterology
Mast cells and histamine
article

S3891 More Than Just a Gut Feeling: Unmasking Systemic Mastocytosis Behind Chronic GI Symptoms

Ashley H. Davis-Yadley, Yuri Sánchez González, G Ramírez, Antoine Khoudari
article en

Abstract

Introduction: Systemic mastocytosis is a rare clonal disorder characterized by abnormal proliferation and accumulation of mast cells in multiple organs. Unlike cutaneous mastocytosis, which is confined to the skin, systemic involvement leads to a broad spectrum of symptoms. Gastrointestinal manifestations are common but often non-specific, mimicking other GI disorders and contributing to delayed or missed diagnoses. Early recognition is essential, as symptoms can significantly impact quality of life. We present a case of a 66-year-old woman with debilitating GI symptoms found to be a result of systemic mastocytosis. Case Description/Methods: A 66-year-old woman with a history of hypertension, gastroesophageal reflux disease, Barrett’s esophagus, and osteoporosis presented with decades-long gastrointestinal symptoms, including abdominal pain, bloating, nausea, vomiting, and diarrhea. Symptoms were intermittently triggered by foods such as alcohol and certain breads and seasonings but sometimes occurred spontaneously with nighttime awakenings. An elimination diet failed to identify consistent triggers and workups for common GI disorders, including celiac disease, were unremarkable. Endoscopic evaluation revealed duodenitis and colitis with histologic features raising suspicion for systemic mastocytosis with CD117+ for mast cells. A bone marrow biopsy later reinforced the diagnosis, demonstrating an activating KIT mutation. Tryptase levels were persistently elevated (>20 ng/mL). These findings fulfilled both the major and minor diagnostic criteria for systemic mastocytosis, specifically the indolent variant. After trials with multiple medications, the patient’s symptoms have been controlled with fexofenadine, montelukast, and famotidine. Other medications included cromolyn, which was discontinued due to poor adherence, and a trial drug, Avapritinib, which was stopped due to lower extremity edema and weight gain. Discussion: This case illustrates the diagnostic and therapeutic challenges of GI involvement in systemic mastocytosis. Early diagnosis enables targeted management with a multidisciplinary team and can significantly improve outcomes and quality of life. A low-histamine diet, escalated antihistamine therapy, and consideration of advanced therapies may also provide symptomatic relief and improve quality of life.

The American Journal of GastroenterologyVol. 120(10S2)
Openalex Percentile: Top 68%
Mast cells and histamine
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.